Study the effectiveness of outpateint treatment of cystic fibrosis exacerbation

Study the Effectiveness of Outpatient treatment in Cystic Fibrosis Patients in Exacerbation Phase

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191112045413N2

Enrollment

Registered

2020-02-14

Start date

2017-10-23

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis. Cystic fibrosis

Interventions

Intervention group: Airway clearance therapy by nebulized Hypertonic saline (3, 5 or 7%) and nebulized Ventolin, chest physiotherapy (at least 4 times a day). Oral antibiotic therapy based on sputum a

Eligibility

Sex/Gender

All

Age

6 Years to 18 Years

Inclusion criteria

Inclusion criteria: Documented diagnosis of CF Exacerbation phase Older than 6 years

Exclusion criteria

Exclusion criteria: Patients unable to perform pulmonary tests because of physical or mental limitations

Design outcomes

Primary

Measure	Time frame
Percent of patients with increased FEV1 values. Timepoint: Before initiation of outpatient treatment and after completion of treatment. Method of measurement: Spirometry machine.;Percent of patients with decreased residual volumes of lungs. Timepoint: Before initiation of outpatient treatment and after completion of treatment. Method of measurement: body box (plethysmograph) machines.;Percent of patients with increased total lung capacities of lungs. Timepoint: Before initiation of outpatient treatment and after completion of treatment. Method of measurement: body box (plethysmograph) machines.;Percent of patients with decreased airway resistance. Timepoint: Before initiation of outpatient treatment and after completion of treatment. Method of measurement: Impulse oscillometry machine.	—

Measure

Time frame

Percent of patients with increased FEV1 values. Timepoint: Before initiation of outpatient treatment and after completion of treatment. Method of measurement: Spirometry machine.;Percent of patients with decreased residual volumes of lungs. Timepoint: Before initiation of outpatient treatment and after completion of treatment. Method of measurement: body box (plethysmograph) machines.;Percent of patients with increased total lung capacities of lungs. Timepoint: Before initiation of outpatient treatment and after completion of treatment. Method of measurement: body box (plethysmograph) machines.;Percent of patients with decreased airway resistance. Timepoint: Before initiation of outpatient treatment and after completion of treatment. Method of measurement: Impulse oscillometry machine.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Modaresi

Tehran University of Medical Sciences

modaresipul@gmail.com+98 21 6147 2727

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026